CLYMClimb Bio Inc. Common Stock
17.28USD-0.35%Mkt Cap: 992.50M $P/E: —3d ago
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, a…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? Climb Bio, Inc. reported its second-quarter 2026 earnings, posting a net loss of US$13.5 million versus US$8.67 million a year earlier, while basic loss per share from continuing operations widened to US$0.18 from US$0.13. Over the first six months of 2026, however, Climb Bio’s net loss narrowed to US$27.22 million from US$29.45 million, with basic loss per share improving to US$0.38 from US$0.44, highlighting mixed progress on its financial profile. With these mixed earnings trends,... | ||